Spray, Stop, Scale: How a Baltimore Startup Revolutionized Trauma Care

BALTIMORE, MD – July 15, 2026 – In the world of medical technology, true disruption often arrives not with a bang, but with a hiss. For Baltimore’s BC3 Technologies, that sound is the deployment of its flagship product, SEAL Hemostatic Wound Spray, an innovation that is not only stopping severe bleeding in seconds but is also fueling one of the region's most explosive MedTech growth stories. The minority-owned company announced today that it is on a trajectory for over 500% revenue growth in 2026, a staggering figure built on a 10x revenue leap from the first half of 2025 to the first half of this year.

This isn't just a story about impressive spreadsheets; it's a narrative of strategic innovation meeting a critical, unmet need. BC3 has managed to translate a complex biochemical solution into a simple, accessible tool, creating a powerful ripple effect that extends from consumer first-aid kits to Ukrainian battlefields and back to the heart of Maryland’s burgeoning life sciences corridor.

The Anatomy of an Innovation

At the core of BC3's success is a product that fundamentally rethinks hemorrhage control. SEAL is the first and only aerosolized hemostatic agent to receive 510(k) clearance from the U.S. Food and Drug Administration, a milestone achieved in March 2023. The technology is built on a foundation of chitosan, a biopolymer derived from crustacean shells known for its blood-clotting properties. When sprayed, the proprietary formula deposits micron-sized chitosan particles to form a robust, occlusive barrier over a wound, initiating clotting almost instantly.

What truly sets SEAL apart from traditional hemostatic agents, like granules or impregnated gauze, is its delivery system. The "Shake-Spray-Pressure" method is intuitive, allowing for rapid application in chaotic and adverse conditions—wind, rain, or low light—where pouring granules or packing a wound can be difficult, if not impossible. The aerosol's "cold" spray technology also induces vasoconstriction, a narrowing of the blood vessels that further aids in staunching blood flow.

The company's pivotal studies submitted to the FDA demonstrated that SEAL was therapeutically equivalent to predicate devices like Celox, a well-known chitosan-based product. Notably, the data suggested that SEAL's application resulted in 50 percent less blood loss than other chitosan-based dressings or granules in certain models. However, some medical technology analysts note that while the FDA clearance is a crucial validation, they await the publication of peer-reviewed clinical literature specifically on SEAL's efficacy in cases of massive, life-threatening hemorrhage. Despite this, its performance in a wide range of pre-hospital scenarios is rapidly building its reputation.

Translating Tech to Traction

The market's response has been nothing short of phenomenal. The company's 10x year-over-year growth for the first half of the year is mirrored by a surge in direct-to-consumer (D2C) sales, which topped $1 million in the first six months of 2026 alone. This D2C boom reveals a significant cultural shift towards personal preparedness. Fueled by its recent eligibility for purchase using Health Savings Accounts (HSAs) and Flexible Spending Accounts, SEAL is finding its way into home emergency kits, hiking backpacks, and vehicle glove compartments across the country.

"BC3 Technologies was founded on the belief that lifesaving innovation is meant to be accessible to everyone," said Wayne Grube, Jr., the company's CEO and Co-Founder. "The growth we are experiencing reflects the increasing recognition that preparedness matters."

This philosophy of accessibility extends to the professional market, where adoption has been swift. Hundreds of EMS, fire, and law enforcement agencies across the U.S. now use SEAL. In a significant local endorsement, the Maryland Institute for Emergency Medical Services Systems (MIEMSS) officially approved the use of SEAL for all Maryland EMS clinicians in December 2024, following a review of the company's research and data from international deployments. The Baltimore City Fire Department is also currently piloting the device, providing a critical real-world testing ground in BC3's own backyard. This institutional adoption validates the product's utility for those who are first on the scene of traumatic injuries, where controlling blood loss is the most critical factor in preventing preventable death.

A Maryland MedTech Blueprint

BC3’s rapid scaling serves as a powerful case study for the strength of Maryland's innovation ecosystem. The company proudly manufactures and distributes all its products from within the state, having invested several million dollars into its local operations over the past three years. This commitment has translated directly into high-value jobs, with the team growing from five employees in 2023 to 15 today, and plans to add more than 20 additional Maryland-based positions in the coming years.

The company's journey has been nurtured by this environment. As a portfolio company of the Maryland Technology Development Corporation (TEDCO), BC3 benefited from early-stage funding and strategic resources designed to help tech startups navigate the perilous "valley of death" between concept and commercialization.

"Maryland has been central to BC3's success from the beginning," Grube confirmed. "From our roots as a Baltimore-based company to becoming part of Maryland’s thriving MedTech community, we’ve benefited from the talent, collaboration, and innovation that make this state a leader in life sciences. We’re proud to continue growing our company, creating jobs, and developing lifesaving technology right here in Maryland."

This symbiotic relationship—where state support fosters innovation and successful startups reinvest in the local economy—is the blueprint that economic developers hope to replicate. BC3's success story is not just its own; it's a testament to a system working as intended.

Securing the Future of First Response

As BC3 scales, its leadership is making strategic moves to solidify its market-leading position. In April 2025, the company was granted a U.S. patent that protects the proprietary chemistry, technology, and methods behind SEAL. This intellectual property fortress is critical for fending off competitors and ensuring a long-term runway for growth and future product development.

The company’s identity as a minority-owned enterprise also provides a unique perspective in an industry striving for greater diversity. This background informs its core mission to break down barriers and ensure that cutting-edge medical solutions are not confined to specialized hospital settings but are available to anyone, anywhere, when seconds matter most. With plans to expand manufacturing capabilities and pursue new industrial safety partnerships and international markets, BC3 Technologies is not just building a business; it is building a new standard of care for emergency response.